All Assays articles – Page 9
-
NewsNew platform will accelerate single-cell analysis workflow
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
-
ArticlePart two: the impact of poor data quality
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
-
WebinarRapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
-
NewsDeveloping a globally-applicable HIV cure
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
-
WebinarThe value of GPCR cell-based assays in drug discovery
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
-
ArticleImproving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
-
ArticleOvercoming the limitations of current drug discovery approaches
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
-
WhitepaperPoster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
ArticleAssay design for Alzheimer’s disease: key considerations and emerging trends
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools ...
-
WebinarIon Channel Drug Discovery - Recent Advances in Novel Non-Opioid Pain Research
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
-
NewsKey insights into vaccine development for herpesviruses
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
-
VideoVideo: Dianthus for identifying Microcycle® hits
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
-
ArticleeBook: Reveal Cell Function With Single-Cell Resolution
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
-
WhitepaperA Guide to Measuring Drug-Target Residence Times
This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times.
-
WhitepaperMEA to probe ALS phenotypes in neuronal disease models
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
-
WhitepaperConsistent, functional lower motor neurons from iPSCs
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
-
WhitepaperWhitepaper: Targeting kinases in the innate immune response
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
-
WhitepaperCase Study: Target discovery for rheumatoid arthritis
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
-
NewsRBM5: potential drug target for acute myeloid leukaemia
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.